Pott C, Dechering DG, Muszynski A, Zellerhoff S, Bittner A, Wasmer K, Mönnig G, Eckardt L. [Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].
Herzschrittmacherther Elektrophysiol 2010;
21:228-238. [PMID:
21113605 DOI:
10.1007/s00399-010-0090-1]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Class I antiarrhythmic drugs are sodium channel inhibitors that act by slowing myocardial conduction and, thus, interrupting or preventing reentrant arrhythmia. Due to proarrhythmic effects and the risk of ventricular tachyarrhythmia, class I antiarrhythmics should not be administered in patients with structural heart disease. Nevertheless, there remains a broad spectrum of arrhythmias--among the most common being atrial fibrillation--that can successfully be treated with class I antiarrhythmic drugs. This review gives an overview on the classification, antiarrhythmic mechanisms, indications, side effects, and application modes of class I antiarrhythmic drugs.
Collapse